Newfoundland Diagnostics is a multinational health-testing company headquartered in London, United Kingdom. The company specializes in the development and distribution of diagnostic health tests, both for self-use and professional applications, [1] offering such products available in major retailers for the first time in the United Kingdom. [2]
Newfoundland Diagnostics was founded in 2020, focusing initially on the distribution of Covid-19 rapid antigen tests. It served as a distributor for Acon Biotech's Flowflex test during the Covid-19 pandemic, becoming a leading player in this field in the United Kingdom, [3] with revenue of over £100m in its first two years of trading. [4]
The company was instrumental in offering diagnostic kits for various medical conditions, such as thyroid function, bowel health, menopause, kidney health, and HIV in a major retailer, notably for the first time in the United Kingdom, [5] and pharmacies across the country. [6] [7]
In June 2023, Newfoundland Diagnostics entered into an exclusive supply agreement with Atomo Diagnostics (ASX: AT1), for the distribution of rapid self-test HIV kits at retailers in the United Kingdom and Europe. [8] [9] This gained notoriety as the world's first commercially available, at-home HIV test, which was sold in major retailers, such as Tesco. [10]
In October 2023, the company responded to the anticipated increase in Strep A cases following the 2022–2023 United Kingdom group A streptococcus outbreak by launching Strep A tests in Tesco stores and pharmacies across the United Kingdom. [11] The company aims to provide enough tests to cover 90% of the United Kingdom's at-home testing market. [12] [13] [14]
As of 2023, Newfoundland Diagnostics holds one of the largest market shares in the United Kingdom for at-home diagnostic tests. [1] The company's networks extend into public health sectors, pharmaceutical industries, and retail channels across the United Kingdom and Europe. It has also begun to make inroads into the European self-test diagnostic market. [15]
{{
cite web}}
: |last1=
has generic name (
help)CS1 maint: multiple names: authors list (
link)
This article needs additional or more specific
categories. (November 2023) |
Newfoundland Diagnostics is a multinational health-testing company headquartered in London, United Kingdom. The company specializes in the development and distribution of diagnostic health tests, both for self-use and professional applications, [1] offering such products available in major retailers for the first time in the United Kingdom. [2]
Newfoundland Diagnostics was founded in 2020, focusing initially on the distribution of Covid-19 rapid antigen tests. It served as a distributor for Acon Biotech's Flowflex test during the Covid-19 pandemic, becoming a leading player in this field in the United Kingdom, [3] with revenue of over £100m in its first two years of trading. [4]
The company was instrumental in offering diagnostic kits for various medical conditions, such as thyroid function, bowel health, menopause, kidney health, and HIV in a major retailer, notably for the first time in the United Kingdom, [5] and pharmacies across the country. [6] [7]
In June 2023, Newfoundland Diagnostics entered into an exclusive supply agreement with Atomo Diagnostics (ASX: AT1), for the distribution of rapid self-test HIV kits at retailers in the United Kingdom and Europe. [8] [9] This gained notoriety as the world's first commercially available, at-home HIV test, which was sold in major retailers, such as Tesco. [10]
In October 2023, the company responded to the anticipated increase in Strep A cases following the 2022–2023 United Kingdom group A streptococcus outbreak by launching Strep A tests in Tesco stores and pharmacies across the United Kingdom. [11] The company aims to provide enough tests to cover 90% of the United Kingdom's at-home testing market. [12] [13] [14]
As of 2023, Newfoundland Diagnostics holds one of the largest market shares in the United Kingdom for at-home diagnostic tests. [1] The company's networks extend into public health sectors, pharmaceutical industries, and retail channels across the United Kingdom and Europe. It has also begun to make inroads into the European self-test diagnostic market. [15]
{{
cite web}}
: |last1=
has generic name (
help)CS1 maint: multiple names: authors list (
link)
This article needs additional or more specific
categories. (November 2023) |